Overview
What it is.
Tirzepatide acts on two gut-hormone pathways — GLP-1 and GIP — involved in appetite and blood-sugar regulation, and is one of the most closely studied dual-agonist compounds in current metabolic research.
Research Areas
- Studied for its role in appetite regulation via dual hormone pathways
- Studied for its role in body-composition research alongside nutrition and training variables
- Studied for its role in blood-sugar regulation
Batch & Testing
Proof, not promises.
Lot
OTP-2607-038
Purity
HPLC ≥99.35%
Released
Jul 24, 2026
Independently tested via HPLC at a third-party laboratory before release. The Certificate of Analysis for this lot ships with your order.
View Certificate of Analysis →Research Deep-Dive
How it works.
Research Deep-Dive
How it works.
Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates two separate gut-hormone pathways involved in appetite and blood sugar regulation, rather than just one. It's the active ingredient in the branded medications Mounjaro and Zepbound.
By activating both the GLP-1 and GIP receptors, tirzepatide combines the appetite-suppressing and insulin-supporting effects of GLP-1 agonism with GIP's separate role in fat metabolism and insulin sensitivity — a dual mechanism researchers believe explains its larger average effect sizes compared with single-pathway GLP-1 medications.
Use Cases Explored
- Programs built around appetite regulation via a dual-hormone mechanism
- Structured weight-management plans paired with nutrition and activity coaching
- Blood-sugar management protocols in type 2 diabetes care
- Maintenance-phase protocols after an initial weight-loss period
The Evidence
SURMOUNT-1 (Phase 3, 2,539 participants)
Average weight loss reached 16.0% on 5 mg, 21.4% on 10 mg, and 22.5% on 15 mg at roughly 72 weeks, versus 2.4% on placebo — with 96% of participants on the higher doses achieving at least 5% weight loss.
SURMOUNT-5 head-to-head trial vs. semaglutide
In a direct comparison, tirzepatide produced greater average weight loss than semaglutide at 72 weeks (-20.2% vs -13.7%) — one of the few head-to-head trials in this drug class.
SURMOUNT-4 maintenance trial
Participants who stopped tirzepatide after an initial 36-week response regained significant weight compared with those who continued treatment, reinforcing that effects require ongoing use, not a one-time course.
Specifications
The essentials.
Specifications
The essentials.
- Vial Capacity
- 3 ml glass vial
- Form
- Lyophilized powder
- Solubility
- Reconstitute with bacteriostatic water
- Storage
- Store in a cool, dry place. Refrigerate at 2–8°C after reconstitution
- Shelf Life
- 24 months lyophilized; 4–6 weeks refrigerated after reconstitution
Metabolic
Tirzepatide
GLP-1/GIP
A dual GLP-1/GIP receptor agonist studied for appetite and metabolic-pathway research.
Size
COA-backed guarantee — independently test any vial; if it's under 99% purity, full refund + testing costs covered.
All products sold by One Tap Peptides are intended for laboratory research use only. Not for human consumption. Not intended for animal use. Not intended for diagnostic or therapeutic purposes.
Related
